

Atezolizumab IMpower110

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Less serious adverse events observed



Other adjustments



Atezolizumab IMpower110

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: First-line treatment of patients with high PD-L1 expression $\geq 50\%$ TC or $\geq 10\%$ IC and who do not have EGFR mutant or ALK-positive NSCLC

Experimental Arm: Atezolizumab

Control Arm: Platinum-based chemotherapy

